Bioink-based 3D bioprinting: Paving the path for regenerative medicine

Three-dimensional (3D) bioprinting has come a long way to have emerged as a transformative technology in bio-fabrication. Bioinks with specific attributes of cellular compatibility, mechanical strength, printability, and biodegradability remain crucial factors and yet a critical challenge. More growth in bioinks is happening with 4D bioprinting due to new developments in supramolecular hydrogels and both naturally and artificially made polymers. iPSCs, organ-on-chip technologies, and microfluidics allow scientists to produce sensitive tissue used for drug therapy and diagnosing diseases. Extrusion, inkjet, and stereolithographic printing let 3D bio-printers mix several materials, preserve cells, and create highly detailed prints. Despite the differences and similarities of AI and automation, they can both be valuable for ensuring quality control. Concerns that limit the clinical use of 3D bioprinting involve regulations, the uneven consistency of bioink, and the importance of ensuring long-term security. It is essential to develop platforms for bioprinting that are scalable, reasonably low-cost, and GMP-compliant and to maintain close collaboration among different fields to achieve all that personalized regenerative medicine and clinical care for cancer, heart disease, neurological diseases, and similar illnesses can offer.